

Elizabeth A Thomas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10667781/elizabeth-a-thomas-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70
papers

3,404
citations

34
h-index

58
g-index

70
ext. papers

3,751
ext. citations

5.8
avg, IF

5.19
L-index

#	Paper	IF	Citations
70	Salivary S100 calcium-binding protein beta (S100B) and neurofilament light (NFL) after acute exposure to repeated head impacts in collegiate water polo players.. <i>Scientific Reports</i> , 2022 , 12, 3439	4.9	1
69	Associations between prognostic index scores and plasma neurofilament light in Huntingtons disease.. <i>Parkinsonism and Related Disorders</i> , 2022 , 97, 25-28	3.6	1
68	Plasma neurofilament light in Huntingtons disease: A marker for disease onset, but not symptom progression. <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 32-38	3.6	6
67	Saliva testing as a means to monitor therapeutic lithium levels in patients with psychiatric disorders: Identification of clinical and environmental covariates, and their incorporation into a prediction model. <i>Bipolar Disorders</i> , 2021 , 23, 679-688	3.8	2
66	Levels of Interleukin-6 in Saliva, but Not Plasma, Correlate with Clinical Metrics in Huntingtons Disease Patients and Healthy Control Subjects. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
65	Reducing gene dosage induces dopaminergic neuronal loss and motor impairments in knockout mice. <i>Communications Biology</i> , 2019 , 2, 125	6.7	8
64	Epigenetic mechanisms in Huntingtons disease 2019 , 73-95		
63	Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntingtons Disease Patients. <i>Frontiers in Molecular Neuroscience</i> , 2019 , 12, 335	6.1	15
62	Complex neuroprotective and neurotoxic effects of histone deacetylases. <i>Journal of Neurochemistry</i> , 2018 , 145, 96-110	6	38
61	Salivary levels of total huntingtin are elevated in Huntingtons disease patients. <i>Scientific Reports</i> , 2018 , 8, 7371	4.9	12
60	Histone Posttranslational Modifications in Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 978, 237-254	3.6	14
59	Beneficial effects of glatiramer acetate in Huntingtons disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. <i>Brain Research</i> , 2017 , 1673, 102-110	3.7	6
58	The Role of Histone Deacetylase Inhibition in the Accumulation and Stability of Disease-Related Proteins 2017 , 159-179		2
57	Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia. <i>NPJ Schizophrenia</i> , 2016 , 2, 16002	5.5	29
56	DNA methylation in Huntingtons disease: Implications for transgenerational effects. <i>Neuroscience Letters</i> , 2016 , 625, 34-9	3.3	24
55	The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntingtons Disease Mice. <i>PLoS ONE</i> , 2016 , 11, e0152498	3.7	55
54	HDAC inhibition imparts beneficial transgenerational effects in Huntingtons disease mice via altered DNA and histone methylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E56-64	11.5	82

53	Disease Modifying Potential of Glatiramer Acetate in Huntingtons Disease. <i>Journal of Huntingtons Disease</i> , 2014 , 3, 311-6	1.9	10
52	Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors. <i>Pharmaceuticals</i> , 2014 , 7, 634-61	5.2	27
51	Behavioral and transcriptome alterations in male and female mice with postnatal deletion of TrkB in dorsal striatal medium spiny neurons. <i>Molecular Neurodegeneration</i> , 2013 , 8, 47	19	9
50	Epigenetic changes at gene promoters in response to immune activation in utero. <i>Brain, Behavior, and Immunity</i> , 2013 , 30, 168-75	16.6	64
49	Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntingtons disease. <i>Neurobiology of Disease</i> , 2012 , 46, 351-61	7.5	139
48	Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. <i>Psychiatry Research</i> , 2012 , 196, 201-6	9.9	27
47	Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntingtons disease mice: implications for the ubiquitin-proteasomal and autophagy systems. <i>Human Molecular Genetics</i> , 2012 , 21, 5280-93	5.6	115
46	Egr-1 induces DARPP-32 expression in striatal medium spiny neurons via a conserved intragenic element. <i>Journal of Neuroscience</i> , 2012 , 32, 6808-18	6.6	13
45	Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. <i>Human Molecular Genetics</i> , 2012 , 21, 3097-111	5.6	40
44	Sphingolipid abnormalities in psychiatric disorders: a missing link in pathology?. <i>Frontiers in Bioscience - Landmark</i> , 2011 , 16, 1797-810	2.8	20
43	Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntingtons disease. <i>Neurobiology of Disease</i> , 2011 , 42, 459-67	7.5	54
42	Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011 , 45, 140-7	2.6	27
41	In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. <i>Human Molecular Genetics</i> , 2011 , 20, 1049-60	5.6	55
40	Genome-wide identification of Bcl11b gene targets reveals role in brain-derived neurotrophic factor signaling. <i>PLoS ONE</i> , 2011 , 6, e23691	3.7	42
39	Changes in Gene Expression in Subjects with Schizophrenia Associated with Disease Progression 2011 , 237-251		1
38	Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntingtons disease. <i>Journal of Neurochemistry</i> , 2010 , 115, 748-58	6	28
37	Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. <i>Nature Neuroscience</i> , 2010 , 13, 1113-9	25.5	454
36	Low Density Lipoprotein Receptor-Related Protein and Apolipoprotein E Expression is Altered in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2010 , 1, 19	5	9

35	Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. <i>Genome Research</i> , 2010 , 20, 403-12	9.7	111
34	A role of apolipoprotein D in triglyceride metabolism. <i>Journal of Lipid Research</i> , 2010 , 51, 1298-311	6.3	45
33	Evidence for disruption of sphingolipid metabolism in schizophrenia. <i>Journal of Neuroscience Research</i> , 2009 , 87, 278-88	4.4	70
32	Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. <i>Molecular Neurobiology</i> , 2009 , 40, 33-45	6.2	46
31	Normal human aging and early-stage schizophrenia share common molecular profiles. <i>Aging Cell</i> , 2009 , 8, 339-42	9.9	38
30	Molecular profiles of schizophrenia in the CNS at different stages of illness. <i>Brain Research</i> , 2008 , 1239, 235-48	3.7	154
29	Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntingtons disease. <i>Neurobiology of Disease</i> , 2008 , 31, 298-308	7.5	47
28	The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntingtons disease transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 15564-9	11.5	240
27	Regulator of G-protein signalling 4 expression is not altered in the prefrontal cortex in schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008 , 42, 740-5	2.6	12
26	Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D. <i>Schizophrenia Research</i> , 2007 , 89, 147-53	3.6	22
25	Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. <i>Journal of Neuroscience Research</i> , 2007 , 85, 757-65	4.4	51
24	Glycolipid and ganglioside metabolism imbalances in Huntingtons disease. <i>Neurobiology of Disease</i> , 2007 , 27, 265-77	7.5	90
23	Gene expression profiling in Brodmanns area 46 from subjects with schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007 , 41, 308-20	2.6	64
22	Striatal specificity of gene expression dysregulation in Huntingtons disease. <i>Journal of Neuroscience Research</i> , 2006 , 84, 1151-64	4.4	47
21	Selective deficits in the expression of striatal-enriched mRNAs in Huntingtons disease. <i>Journal of Neurochemistry</i> , 2006 , 96, 743-57	6	112
20	Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders. <i>Molecular Neurobiology</i> , 2006 , 34, 109-28	6.2	33
19	Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. <i>Schizophrenia Research</i> , 2005 , 72, 259-66	3.6	18
18	Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimers disease: no relation to apolipoprotein E expression or genotype. <i>Biological Psychiatry</i> , 2003 , 54, 136-41	7.9	48

17	Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2003 , 69, 421-7	2.8	27
16	Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. <i>Biological Psychiatry</i> , 2003 , 54, 616-22	7.9	38
15	The neurobiology of apolipoproteins in psychiatric disorders. <i>Molecular Neurobiology</i> , 2002 , 26, 369-88	6.2	26
14	Novel isoform of insulin receptor substrate p53/p58 is generated by alternative splicing in the CRIB/SH3-binding region. <i>Journal of Biological Chemistry</i> , 2002 , 277, 24728-34	5.4	21
13	Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. <i>Journal of Neurochemistry</i> , 2001 , 76, 789-96	6	52
12	Apolipoprotein D mRNA expression is elevated in PDAPP transgenic mice. <i>Journal of Neurochemistry</i> , 2001 , 79, 1059-64	6	22
11	Insulin receptor substrate protein p53 localization in rats suggests mechanism for specific polyglutamine neurodegeneration. <i>Neuroscience Letters</i> , 2001 , 309, 145-8	3.3	17
10	Evolutionarily distinct classes of S27 ribosomal proteins with differential mRNA expression in rat hypothalamus. <i>Journal of Neurochemistry</i> , 2000 , 74, 2259-67	6	25
9	Pertussis toxin treatment prevents 5-HT(5a) receptor-mediated inhibition of cyclic AMP accumulation in rat C6 glioma cells. <i>Journal of Neuroscience Research</i> , 2000 , 61, 75-81	4.4	24
8	The endogenous lipid oleamide activates serotonin 5-HT7 neurons in mouse thalamus and hypothalamus. <i>Journal of Neurochemistry</i> , 1999 , 72, 2370-8	6	37
7	Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. <i>Biochemical Pharmacology</i> , 1999 , 58, 1807-13	6	48
6	RGS9: a regulator of G-protein signalling with specific expression in rat and mouse striatum. <i>Journal of Neuroscience Research</i> , 1998 , 52, 118-24	4.4	75
5	Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. <i>Journal of Neuroscience Research</i> , 1997 , 50, 1047-52	4.4	155
4	Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system 1997 , 50, 1047		3
3	Involvement of the M2 muscarinic receptor in contractions of the guinea pig trachea, guinea pig esophagus, and rat fundus. <i>Biochemical Pharmacology</i> , 1996 , 51, 779-88	6	38
2	The 5HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: a mechanism for neuronal suppression of reactive astrocytes. <i>Glia</i> , 1996 , 17, 317-26	9	77
1	Functional role of M2 muscarinic receptors in the guinea pig ileum. <i>Life Sciences</i> , 1995 , 56, 965-71	6.8	36